Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood filter aims to calm deadly inflammation in septic shock

NCT ID NCT07715110

Disease control Sponsor: Miguel Sanchez Garcia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This pilot trial tests whether a special cartridge placed in a blood-filtering machine can improve outcomes for people with septic shock, a severe and often deadly infection response. The cartridge is designed to remove inflammatory molecules from the blood, which may reduce organ damage and help patients recover. The study includes two groups: those with standard septic shock and those with a more severe form called refractory septic shock. Researchers will compare a combination of survival and early improvements in inflammation, organ function, and blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A resin-based hemoadsorption cartridge inserted into a continuous renal replacement therapy circuit to filter inflammatory mediators from the blood.
What this could lead to
If successful, this approach could provide a new way to reduce inflammation and organ damage in septic shock, potentially lowering the high death rate.
What could go wrong
This is a very small pilot study with only 16 participants, so results may not apply broadly. The treatment is experimental and may not improve outcomes or could cause complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 16 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All of the following: * Age ≥ 18 years. * Diagnosis of septic shock per Sepsis-3, with an identified or highly probable infectious focus. * Meeting the operational definition of one of the two severity strata (SS or RSS) detailed in 6.1. * Onset of septic shock within the last 24 hours (applied identically to both strata). * Large-bore vascular access. * Informed consent signed by the legal representative. Exclusion Criteria: * Decision to limit life-sustaining therapy made or anticipated within the next 48 hours. * Absolute contraindication to anticoagulation with heparin and citrate. * Predominant non-septic shock (hemorrhagic, primary cardiogenic, obstructive). * Ongoing pregnancy. * Platelet count \< 20,000/µL. * Significant pharmacological immunosuppression: chronic corticosteroids at doses \> 20 mg/day prednisone equivalent, biologics within the last 6 months, cytotoxic chemotherapy within the last 4 weeks. * Solid organ or hematopoietic stem cell transplantation. * Concurrent participation in another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemoadsorption are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis multiple organ dysfunction syndrome Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemoadsorption Hemoperfusion Multiple organ dysfunction Sepsis Septic shock, vasopressor resistance

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ervigio Corral-Torres

    Madrid, Es-Md, 28040, Spain

  • Hospital Clínico San Carlos

    Madrid, Es-Md, 28040, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.